+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Predisposition Biomarkers: Technologies and Global Markets

  • ID: 4849352
  • Report
  • October 2019
  • Region: Global
  • 72 Pages
  • BCC Research
UP TO OFF
until May 31st 2020
1 of 4

FEATURED COMPANIES

  • Abcodia Ltd.
  • Adx Neurosciences Nv
  • BioMerieux Inc.
  • Compugen Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Mirnaxbiosens, S.L
  • MORE

Report Includes:

  • An overview of technologies and global markets for the predisposition biomarkers
  • Analyses of the global market trends with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Information on recent key technical advances in different predisposition biomarkers, as well as the extent of adoption by commercial customers and regulatory authorities
  • Identification of key areas of growth and the key strategies of major players in the market
  • A look at recent diagnostic test developments and revelations as well as knowledge of how they will influence selected clinical markets

This comprehensive report provides an in-depth assessment of the global market for predisposition biomarker technologies. The report’s key objective is to analyze areas of opportunities, key developments and the impact of this technology on industry, specifically the pharmaceutical, biotechnology, and healthcare sectors. The analysis also reviews the adoption of predisposition biomarker technologies in developed and emerging markets.

This report details recent key technical advances in different predisposition biomarkers, as well as the extent of adoption by commercial customers and regulatory authorities. The report intends to identify key areas of growth. The report also studies the key strategies of major players in the market and the impact of new technological developments.

Reasons for Doing This Study

Biomarkers are indicators of a biological state long before the appearance of its symptoms. A genetic predisposition biomarker is associated with increased or, in certain cases, decreased chances of developing a health disorder in an individual who, from a clinical viewpoint, has not yet suffered from that medical condition. This largely includes the identification of genetic biomarkers that suggest an increased likelihood of developing cancer in a later stage of life. Predisposition biomarkers are largely considered when an individual has a family history suggesting an inherited risk for a specific health disorder. The biomarkers can guide an individual in decisions related to their future medical care.

The report provides a detailed and proprietary analysis of the predisposition biomarker market. This report should interest drug manufacturers, biotech companies, contract research organizations, healthcare providers, regulatory agencies and government organizations. The report analyzes pricing, market size, and market norms and regulations. This comprehensive analysis includes an easy to understand graphical representation of facts and competitive analysis of market players.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abcodia Ltd.
  • Adx Neurosciences Nv
  • BioMerieux Inc.
  • Compugen Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Mirnaxbiosens, S.L
  • MORE

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Market Definition
  • Key Takeaways
  • Key Recommendations

Chapter 4 Market Breakdown by End User

  • Hospitals
  • Research Institutes

Chapter 5 Market Breakdown by Application

  • Cancer
  • Neurological Diseases
  • Cardiovascular Diseases
  • Diabetes
  • Other Diseases

Chapter 6 Market Breakdown by Region

  • North America
  • United States
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Rest of Asia-Pacific
  • Rest of World

Chapter 7 Patent Review and New Developments

  • Recent Developments

Chapter 8 Competitive Landscape

  • BioMerieux Inc.
  • Recent Developments
  • F. Hoffmann-La Roche Ltd.
  • Recent Developments
  • Merck KGaA
  • Recent Developments
  • QIAGEN N.V.
  • Recent Developments
  • Thermo Fisher Scientific Inc.
  • Recent Developments
  • Myriad Genetics Inc.
  • Recent Developments

Chapter 9 Company Profiles

  • Abcodia Ltd.
  • Admera Health
  • Adx Neurosciences Nv
  • Amprion Inc.
  • Bio-Rad Laboratories Inc.
  • Compugen Ltd.
  • Epigenomics Ag
  • Mirnaxbiosens, S.L
  • Oncimmune Ltd.
  • Optos Plc

List of Tables
Summary Table: Global Market for Predisposition Biomarkers, by Application, Through 2024
Table 1: Global Market for Predisposition Biomarkers, by End User, Through 2024
Table 2: Global Market for the Application of Predisposition Biomarkers in Hospitals, by Region, Through 2024
Table 3: Global Market for the Application of Predisposition Biomarkers in Research Institutes by Region, Through 2024
Table 4: Research Institutes Working on Cancer Studies Across the Globe
Table 5: Global Market for Predisposition Biomarkers, by Application, Through 2024
Table 6: Clinically Relevant Biomarkers for Lung Cancer
Table 7: Global Market for Cancer Predisposition Biomarkers, by Region, Through 2024
Table 8: Global Incidence and Prevalence of Common Neurological Diseases, 2017
Table 9: Global Market for Neurological Predisposition Biomarkers, by Region, Through 2024
Table 10: List of Biomarkers Associated with CVDs
Table 11: Global Market for Predisposition Biomarkers for CVDs, by Region, Through 2024
Table 12: Global Market for Diabetes Predisposition Biomarkers, by Region, Through 2024
Table 13: Characteristics of Biomarkers for Prediabetes, Diabetes and Associated Complications
Table 14: Global Market for Other Applications of Predisposition Biomarkers, by Region, Through 2024
Table 15: Global Market for Predisposition Biomarkers, by Region, Through 2024
Table 16: North American Market for Predisposition Biomarkers, by Country, Through 2024
Table 17: North American Market for Predisposition Biomarkers, by End User, Through 2024
Table 18: North American Market for Predisposition Biomarkers, by Application, Through 2024
Table 19: Active Early Detection Research Network Grants in the U.S., 2019
Table 20: Funding for Research on Biomarkers for Alzheimer’s in Canada
Table 21: European Market for Predisposition Biomarkers, by Country, Through 2024
Table 22: European Market for Predisposition Biomarkers, by End User, Through 2024
Table 23: European Market for Predisposition Biomarkers, by Application, Through 2024
Table 24: Cancer Incidences and Mortalities in Europe, 2018
Table 25: Major Neurological Incidences in Europe in 2017
Table 26: Asia-Pacific Market for Predisposition Biomarkers, by Country, Through 2024
Table 27: Asia-Pacific Market for Predisposition Biomarkers, by Application, Through 2024
Table 28: Asia-Pacific Market for Predisposition Biomarkers, by End User, Through 2024
Table 29: Cancer Incidence and Mortalities in Asia-Pacific, 2018
Table 30: Active Dementia Research Grants in Australia
Table 31: Rest of the World Market for Predisposition Biomarkers, by Application, Through 2024
Table 32: Rest of the World Market for Predisposition Biomarkers, by End User, Through 2024
Table 33: Number of Patents, by Country, January 2015-May 2019
Table 34: Number of Patents, by Company/Organization
Table 35: Number of Patents Registered, by Year
Table 36: BioMerieux Inc.: Financial Analysis, 2017 and 2018
Table 37: F. Hoffmann-La Roche Ltd.: Financial Analysis, 2017 and 2018
Table 38: Merck KGaA: Financial Analysis, 2017 and 2018
Table 39: QIAGEN N.V.: Financial Analysis, 2017 and 2018
Table 40: Thermo Fisher Scientific Inc.: Financial Analysis, 2017 and 2018
Table 41: Myriad Genetics Inc.: Financial Analysis, 2017 and 2018

List of Figures
Summary Figure: Global Market for Predisposition Biomarkers, by Application, 2018-2024
Figure 1: Global New Cancer Cases, by Type, 2018
Figure 2: Prevalence of Cancer, by Type, 2018
Figure 3: BioMerieux Inc.: Revenue, by Region, 2018
Figure 4: F. Hoffmann-La Roche Ltd.: Revenue, by Operating Segment, 2018
Figure 5: Merck KGaA: Revenue, by Region, 2018
Figure 6: QIAGEN N.V.: Revenue, by Region, 2018
Figure 7: Thermo Fisher Scientific Inc.: Revenue, by Region, 2018
Figure 8: Myriad Genetics Inc.: Revenue, by Operating Segment, 2018

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abcodia Ltd.
  • Admera Health
  • Adx Neurosciences Nv
  • Amprion Inc.
  • Bio-Rad Laboratories Inc.
  • BioMerieux Inc.
  • Compugen Ltd.
  • Epigenomics Ag
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • Mirnaxbiosens, S.L
  • Myriad Genetics Inc.
  • Oncimmune Ltd.
  • Optos Plc
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown
Adroll
adroll